インフォショップ ホームへ 株式会社グローバルインフォメーション
サイトマップ
その他のカテゴリ

商品カタログ

医療/バイオの調査資料販 MEDINFO.JP

バイオシミラー特集
バイオシミラー特集ページ バイオシミラーに関連したレポートを紹介致します。

Translational Cancer Medicine 公式サイト

Outsourcing Asia Summit 2009 公式サイト

Global Healthcare Congress 2009 公式サイト

BioMedical Asia 2009 公式サイト

China 2009 Pharmaceutical R&D Summit 公式サイト

Drug Discovery & Development of Innovative Therapeutics Japan 2009 公式サイト

World Vaccine Congress Asia 2009 公式サイト

Drug Discovery & Development of Innovative Therapeutics 2009 公式サイト
English Korean Chinese
【 英文市場調査報告書 】

欧州における糖尿病診断市場に関する戦略的分析

Strategic Analysis of the European Diabetes Diagnostics Market

商品コード : 27561 Frost & Sullivan
出版日 : 2005/02
発行 : Frost & Sullivan
電話でのお問い合わせ
価格情報
概要 原文目次
※この商品は英文にてご提供いたします。

Abstract

Increasing Levels of Diabetes Awareness in Europe offer a Growing Market for Diabetes Diagnostic Monitoring Systems

In line with global trends, diabetes has become a multibillion-dollar industry in Europe. Type 2 diabetes alone contributes to an annual economic cost of ?29 billion between Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. Increasing levels of diabetes awareness among patients, physicians and healthcare professionals has given rise to a market for a variety of devices designed to precisely monitor glucose while easing the burden of frequent blood tests. Traditionally, urine testing has been the only method for gauging blood glucose levels in the patients system. However, owing to its imprecise nature and inability to detect low blood glucose levels, there is a growing demand for portable glucose meters that are compact, user-friendly and efficiently accurate.

This Frost & Sullivan research service covers the European diabetes diagnostics market. The study focuses on market dynamics, current market drivers and provides forecasts for emerging trends. It also looks at the industry challenges and potential threats and makes strategic recommendations for boosting market share.

Point-of-Care Testing is the Largest Profit Making Segment in the Market

Early detection of diabetes is very important in managing the disease. Vast technological improvements in the point-of-care (PoC) technology have made PoC testing an easy approach to the conventional monitoring techniques, since it provides quick and simple results. With the increasing complexity of data and analysis interpretation, PoC testing is expected to play a key role in the fight against diabetes and will dominate the market over clinical diagnostics. The clinical diagnostic segment has seen numerous consolidations of laboratories and industry participants. This has meant that the same numbers of patients are now sampled by fewer laboratories, thus increasing business per customer and allowing laboratories to negotiate better deals from suppliers.

The level of PoC and laboratory testing will vary little over the next several years. However, the use of glycated haemoglobin (HbA1c) testing is expected to rise slightly as general practitioner surgeries, healthcare and outpatient clinics and small hospital-based laboratories more readily adopt this technology. "A large part of HbA1c testing is being transferred to outsourced service providers or reference laboratories, where tests are being processed at prices far cheaper than hospital-based laboratories," notes the analyst.

Anticipating Customer Needs and Improving Diagnostic Technology will Drive Future Growth

The European diabetes diagnostic market has reached a mature stage and this is likely to limit profitability. Manufacturers will have to identify the customers unmet needs and develop competent technologies that focus on dedicated systems to improve cost efficiency and profitability. Despite increasing the levels of diabetes awareness, at least one-third of the people with diabetes are unaware of their condition. While this highlights a vast market for diagnostic equipment, patients and potential patients need to be educated to encourage the use of testing and monitoring as part of regular physical examinations.

"Though conventional blood testing, which is mainly conducted through PoC products (hand-held, desktop and laboratory) remains the gold standard in glucose monitoring, todays pinprick meters do faster tests, using lesser blood sample quantities than possible before," says the analyst. "However, challenges still remain for more patient-friendly screening and treatments that can gather a wealth of data for diabetes management and information." The future of diabetes care is clustered with non-invasive devices and technologies that make glucose regulation far more accurate and easier to manage.

Table of Contents

1 STRATEGIC ANALYSIS OF THE EUROPEAN DIABETES DIAGNOSTICS MARKET

  • Overview
  • Research Scope and Methodology

Introduction and Background

  • Key Definitions and Abbreviations
  • Exchange Rates
  • Introduction
  • Overview
  • Global Projections I-III
  • Types of Diabetes I-II
  • Diabetes Complications I-II
  • Glucose Testing I-III
  • Economic Impact

Market Dynamics

  • Market and Technology Trends I-II
  • Industry Challenges
  • Key Market Drivers
  • Market Drivers
  • Key Market Restraints
  • Market Restraints
  • Market Status and Size
  • Commercial and Emerging Trends
  • Commercial Testing

Total Market Forecasts

  • Assumptions
  • Key Market Engineering Measurements
  • EU Diabetes Diagnostics Market Revenue Forecast
  • Segmentation of Diabetes Diagnostic Market
  • Revenue Forecasts by Segments
  • Segmentation Revenue Analysis
  • Company Profiles

Strategic Analysis and Recommendations

  • Major Challenges and Strategies
  • Strategic Anticipation
  • Potential Threats
  • Competitive Framework
  • Three Levels of Strategies
  • Pricing Strategy
  • Meeting the Challenge
  • What can be Expected in the Future?

Frost & Sullivan Awards

  • Frost & Sullivan Awards
  • Competitive Strategy Leadership Award
  • Product Innovation Award
  • Technology Innovation Award
  • Growth Strategy Leadership Award
  • Marketing Strategy Leadership Award
  • Industry Participants
  • Decision Support Databases

Frost & Sullivan

  • Healthcare Team
  • Our Capabilities
概要 原文目次
※この商品は英文にてご提供いたします。
【 英文市場調査報告書 】
欧州における糖尿病診断市場に関する戦略的分析
Strategic Analysis of the European Diabetes Diagnostics Market
出版日 : 2005/02
電話でのお問い合わせ
この商品について問い合わせる
この商品のサンプル(抜粋)を依頼する
価格

※ドル建て価格の商品のお支払いは、為替レート (TTS: 93.56) 換算による円建てのご請求書にて承ります。

US $ 5,450 換算 -> ¥ 509,902 (税抜) Hard Copy & Web Access (Regional License)
US $ 4,950 換算 -> ¥ 463,122 (税抜) Web Access
商品コード : 27561
関連カテゴリ : 糖尿病
関連する商品をキーワードで検索する